AstraZeneca

Dicot Pharma has completed enrollment and dosing of all participants in its Phase 2a clinical trial evaluating LIB-01 for erectile dysfunction treatment.

Evotec has joined the NURTuRE-AKI consortium led by Kidney Research UK to establish the world's most comprehensive patient cohort for acute kidney injury research.

A BMJ investigation has revealed evidence of serious misreporting in two clinical trials that were pivotal to ticagrelor's approval by the FDA and UK regulators.

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, including an upfront payment of almost $1 billion and $300 million in milestone-based payments.

ANGLE presented breakthrough data at EACR 2025 demonstrating DNA dual analysis combining CTC-DNA and ctDNA from single blood samples, revealing 53% of mutations found exclusively in CTCs in lung cancer patients.

A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.

AstraZeneca has selected and licensed Quell Therapeutics' lead CAR-Treg cell therapy candidate for inflammatory bowel disease, triggering a $10 million milestone payment.

Antares Therapeutics launched with $177 million in Series A financing co-led by five major healthcare investment firms to develop first-in-class precision medicines for cancer and other serious diseases.

Alexion, AstraZeneca's rare disease division, has entered a collaboration with AI platform provider Pangaea Data to develop an artificial intelligence clinical decision support system for detecting hypophosphatasia in adults.

National Resilience announced plans to wind down six manufacturing facilities across California, Massachusetts, and Florida, citing that capacity expansion has outpaced industry demand.